Target intelligence / Profile preview

Pyridoxine 5'-phosphate oxidase (PNPO)

Target
PNPO
Molecular classification
Enzyme, Oxidoreductase, Flavin mononucleotide (FMN)-dependent enzyme
01

Overview

Pyridoxine 5'-phosphate oxidase is a homodimeric, FMN-dependent oxidoreductase enzyme that catalyzes the final, rate-limiting step in the biosynthesis of pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B6. It oxidizes both pyridoxine 5'-phosphate and pyridoxamine 5'-phosphate to PLP, which is an essential cofactor for numerous enzymatic reactions, particularly in amino acid and neurotransmitter metabolism. Deficiency of this enzyme, usually due to genetic mutations in the PNPO gene, leads to reduced PLP levels, causing severe neurological disorders such as neonatal epileptic encephalopathy. The enzyme has a highly conserved structure with distinct species-specific regulatory features and operates via a tightly regulated catalytic cycle affecting PLP homeostasis. There are no known drugs that directly modulate PNPO, but PLP supplementation is the accepted treatment in deficiency states.

Other names
Pyridoxamine 5'-phosphate oxidasePyridoxamine (pyridoxine) 5′-phosphate oxidasePNPOx
02

Mechanism of action

Oxidation of pyridoxine 5'-phosphate and pyridoxamine 5'-phosphate to form active pyridoxal 5'-phosphate, a coenzyme participating in numerous metabolic reactions

03

Biological functions

Vitamin B6 metabolismBiosynthesis of pyridoxal 5'-phosphate (PLP)Amino acid metabolismMaintenance of PLP homeostasis
04

Disease associations

Neurological disease (notably neonatal epileptic encephalopathy due to PNPO deficiency)Potential cancer relevance (due to altered vitamin B6 metabolism in some cancer cells)Other inborn errors of metabolism
05

Safety considerations

Potential for neurotoxicity with excessive PLP/vitamin B6 supplementationDifficulty treating PNPO deficiency as only PLP, not pyridoxine, is effectiveRisk of inadequate treatment in vitamin B6-dependent epilepsies unless correct diagnosis is made
06

Interacting drugs

None approved as direct inhibitors or activators; however, therapeutic pyridoxal phosphate (PLP) or pyridoxine supplementation is used in PNPO-deficiency-related epilepsy to bypass the block
07

Biomarkers

PLP (pyridoxal 5'-phosphate) levels in plasma or CSF (for diagnosis of deficiency)Accumulation of upstream vitamin B6 metabolites in some metabolic disorders

Beyond the preview

Go deeper on Pyridoxine 5'-phosphate oxidase (PNPO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyridoxine 5'-phosphate oxidase (PNPO).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call